Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

CorMedix Inc.

35 indications, side-by-side phase, drug & LoA

$8.74

-0.22 (-2.46%)

B 65Pipeline Score Undervalued Biotech · Commercial
Market Cap
626.05 M
EPS
2.39
P/E Ratio
3.8 $
Value Trade
6.85 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    127.43 M

  • R&D Expenses

    7.21 M

  • Operating CF

    42.38 M

  • Total Assets

    815.64 M

  • Total Liabilities

    378.59 M

  • Equity

    437.05 M

  • D/E Ratio

    12,345

0.38 %
Week
6.54 %
1 Month
12.87 %
3 Month
-16.26 %
6 Month
18.22 %
5 Year
-50.13 %
All Time
Cash Data
Profitable

  • Cash Position

    178.09 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 14, 2026
Overview
Volume
969.81 K
52 Week Range
6.13 - 17.43
% held by Insiders
7.86 %
% held by Institutions
52.86 %
Enterprise Value
592.19 M
Total Shares
78.38 M
Short %
20.51 %
Float Shares
70.94 M
Company Description
HQ: 389 INTERPACE PKWY, SUITE 450,...
Employees:191
https://www.cormedix.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 3 data readout example
REZZAYO (rezafungin) Prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation
Phase 3
—
Small Molecules
Infectious Diseases
REZZAYO (rezafungin) Prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation
Phase 3
—
Small Molecules
Infectious Diseases
REZZAYO (rezafungin) Prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation
Phase 3
—
Small Molecules
Infectious Diseases
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B65
Pipeline Score
$2.4B
Pipeline Value
Undervalued
Valuation Signal
14
Drugs Scored
3.8x
rNPV / MCap
Top 93%
Micro Cap
(rank 64 of 905)
Percentile Rank
CorMedix Inc. holds a solid B-grade pipeline (65/100), with $5.9B risk-adjusted pipeline value, led by Single-Dose Oritavancin Diphosphate in Wound Infection (Phase 3), across $89B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Single-Dose Oritavancin Diphosphate
Small molecule		Wound InfectionPhase 3NCT0125273255% $1.7B COMPLETED 1,987 - -Jun 1, 2013 -May 5, 2021
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
REZZAYO
candidemia,invasive candidiasis
Phase 3
2025-08-07
REZZAYO
candidemia,invasive candidiasis
Phase 3
2025-08-07
REZZAYO
candidemia,invasive candidiasis
Phase 3
2025-08-07
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CRMD
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CRMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CRMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CRMD
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
CRMD Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
CRMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest CorMedix Inc. (CRMD) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How CRMD ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Urinary Tract Infections #2 of 4 PHASE 2 Meropenem-Vaborbactam + Antibiotics
GSK PFE QGEN
$9.63B 0 CONTENDER
Bacterial Infections #6 of 31 PHASE 3 catheter lock + Heparin
PFE SNY GSK
$10.5B 0.9 CONTENDER